We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ekf Diagnostics Holdings Plc | EKF | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.15 | 4.11% | 29.15 | 16:35:24 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 28.60 | 28.50 | 28.60 | 29.15 | 28.00 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 28/03/2023 | Final | GBP | 0.012 | 02/11/2023 | 03/11/2023 | 01/12/2023 |
| 29/03/2022 | Interim | GBP | 0.012 | 03/11/2022 | 04/11/2022 | 01/12/2022 |
| 29/03/2022 | Final | GBP | 0.012 | 03/11/2022 | 04/11/2022 | 01/12/2022 |
| 30/03/2021 | Final | GBP | 0.011 | 04/11/2021 | 05/11/2021 | 01/12/2021 |
| 15/07/2019 | Interim | GBP | 0.01 | 16/11/2020 | 17/11/2020 | 01/12/2020 |
| 15/07/2019 | Final | GBP | 0.01 | 05/11/2020 | 06/11/2020 | 01/12/2020 |
| Top Posts |
|---|
Posted at 26/7/2024 12:23 by wan James...EKF completed two fermentation runs that will generate revenue in 2024. EKF previously reported that this will lead to further growth in 2024 as the two new customers scale up (initial fermentation runs prove the process and generate less than the contracts to produce the product).So, we may get at least part of your answer if/when (more a case of when in my view) the contracts fully materialise. And, if you believe what Mills stated a few days ago, that there is only 5 or 6 precisions fermentation facilities in the world as good as EKF's, then it casts some light on why it has been referred to by EKF as cutting-edge/state-o And as I have said numerous times, we should get better insights to what EKF fermentation facility is capable of producing when EKF launch their new global website (which has been pushed into the current quarter). To be clear, neither the facilities, nor certain targeted products, are run-of-the-mill! Likewise, the new website will be unlike the current version! Interestingly, and aside from the fermentation contracts for other players, being able to produce differentiated and important enzymes, could also further differentiate EKF's diagnostic capabilities and diagnostic products. |
Posted at 24/7/2024 11:10 by wan I don't run entirely with the inevitability of EKF being bought out in the short term, unless future progress and prospects are not properly reflected in the share price. But I note that there is a seller out there that might bring that scenario about (maybe that's a response to the 'pause' in dividends?).However, given the potential enabled by EKF's precision fermentation facility (about which we will find out more detail in due course) high-value contracts will hopefully feature going forwards, and I would not discount key partnerships featuring around certain developments. These type of announcements would obviously cause upgrades accordingly. In short, I want to see both the investment to date, and at least some of the potential realised and accordingly reflected in the share price. We are obviously not there yet, but there is already tangible evidence of very good growth prospects for both divisions, and high-growth potential for the fermentation facility! Interestingly, EKF's precision fermentation facility could ratchet up the growth dynamics of their point-of-care division, if they move forward with producing diagnostic enzymes that enable the manufacture of additional high-margin EKF diagnostic products. In my view, for the patient investor, there is early evidence that indicates there is a combination of good progress and much further potential to be realised. And maybe even the resumption of dividend payments. |
Posted at 23/7/2024 08:54 by wan Thanks for the heads-up Earwacks.According to Mills, he could only comment and refer back to what was said at the time of AGM meeting/statement i.e. what's already in the public domain (and rightly so) as EKF has a trading update coming out this week (later stating within the next 7 days). Mills also reiterated that the references he made regarding EKF's fermentation facility were in the public domain. Excerpts from the AGM Statement - The expected scaling up of fermentation services at our South Bend site continues as expected, for both existing customers, as well as new customers looking to take advantage of our increased capacity. Sales for fermentation services in Q1 2024 are up 156% year-on-year, and so we remain in-line with our previous guidance for a gradual build-up in revenues and profitability from this side of the business. With very pleasing trading in the first quarter of 2024, particularly with a focus on our key higher margin product lines, we remain confident that our overall financial performance for the year will be in-line with management expectations, and that 2024 will be a year of significant momentum in terms of both EBITDA margins and cash generation. Chris Mills recent EKF comments (at 14:35 minutes) - A very interesting aspect was that EKF have their own enzymes, presumably derived via their highly specialist processes and capabilities, which can be used to enable and manufacture diagnostics, and that this is an active area of consideration. Staying with diagnostic enzymes; recently (post 50) I mention that an interesting aspect that recently piqued my interest was the development of diagnostic sensors with an enzyme composition, and in particular, with a reagent layer containing β-hydroxybutyra Based on existing EKF products e.g. Biosen and Lactate Scout Sport, EKF may also have the capability to include Lactate within such a sensor/diagnostic, which again combining both ketone sensing (BHB) and lactate into one sensor is already a particular area of interest. |
Posted at 30/6/2024 11:13 by wan Most readers already appreciate that EKF manufacture Beta-Hydroxybutyrate enzyme(BHB).We also know that EKF have the capacity to significantly increase the production of BHB. And that EKF is now manufacturing a new white label BHB product for Thermo Fisher, itself effectively demonstrating that a large addressable market exists going forward. EKF Life Sciences had β-HB sales of £12.1m in 2023 and recently reported that stronger growth expected from β-HB sales, up 7% in Q1 2024 compared to Q1 2023, is beginning to come through as they benefit from the positive impact of White Label contracts for β-HB with Thermo Fisher and Cardinal. An interesting aspect that recently piqued my interest is the development of diagnostic sensors with enzyme composition, and in particular, with a reagent layer containing β-hydroxybutyra Beyond the management of diabetic ketoacidosis, one of the markets such sensors are looking to [also] address is the personal nutrition and wellness market, where BHB is of particular interest in terms of supplements and performance, with reports indicating that the ketones market is going to experience strong, multi-year rates of growth. With additional BHB production capacity available via EKF's new and operational state-of-the-art fermentation facility, and beyond supplying Thermo and Cardinal (and others), addressing additional BHB markets might be a consideration (or even intentional). That aside, and beyond just BHB, it is clear that 'precision' fermentation is receiving strong interest and demand! |
Posted at 10/6/2024 11:06 by wan I am drawn to the recent acquisition of Point-of-Care player Lumira Dx by Roche for $295 million upfront and another cache of up to $55 million, which on its own effectively demonstrates the interest in point-of-care diagnostics.In its last set of recorded revenues, Lumira had $9.2 million in non-COVID sales in the first half of 2023, which equates to around £7m sterling. In 2023, EKF recorded non-Covid sales of £48.7m, with point-of-care recording £32.4m (excluding clinical chemistry and Covid related revenues), which is equivalent to a comparison of around £16m first half revenues compared to Lumira's £7m. (note that EBITDA for the first three months of the year is already showing a c.20% improvement on Q1 2023, and that 2024 will be a year of significant momentum in terms of both EBITDA margins and cash generation). Roche is paying a combined £275m sterling compared to EKF's current market cap of £133m sterling. I appreciate that Roche predominantly bought the technology and not the revenues per se, but it shines at least some light on the value of EKF's globally installed base, and the value of the embedded technology which is further demonstrated by EKF's growing recurring revenues (95 million individual test consumables in 2023). Importantly, EKF's point-of-care technology development is not standing still, which will no doubt be significantly augmented by EKF's new fermentation facility (in contrast to Lumira) e.g. developing and manufacturing enabling consumable diagnostic products (and not just for EKF, but also for medical diagnostics, pharmaceuticals, and industrial applications, facilitating transformative breakthroughs in healthcare and beyond). EKF are doing what Private Equity would do in terms of rationalisation and operational efficiency improvements, which gives pause for thought as to whether AIM is 'ultimately' the right place for listing EKF, or whether those measures and an AIM listing makes EKF an attractive acquisition target (surely it does at the current share price?), and indeed whether Harwood Capitals 29.169% holding will ensure EKF does not succumb to a lowball offer. EKF appears underappreciated (some would say deservedly), despite being debt free, cash generative, undervalued and primed for further growth in 2024. It will therefore be interesting to see whether there is anything beyond a technical pullback in the share price as the quieter summer season approaches, or whether the summer turns out to be an extended hunting season for acquiring UK stocks, with the possibility of EKF being on the menu! Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
Posted at 01/6/2024 09:50 by wan Excerpts from EKF's RNS 26 October 2023 regarding the Opening of new US State-of-the-art Life Science Manufacturing FacilityUnique GMP capabilities, addresses a significant gap in the US market for scalable mid-volume manufacturing EKF Life Sciences is a specialist global manufacturer of high-quality enzymes and custom products for use in diagnostic, pharmaceutical and industrial applications. The Company is at the forefront of supporting life sciences global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver breakthrough discoveries and advancements in healthcare and medicine. The Company's state-of-the-art facilities and leading technical expertise in specialist enzyme production uses precision microbial fermentation and cutting-edge downstream processes, to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. The new 24,000 square foot state-of-the-art facility addresses a significant gap in the US market for mid-volume manufacturing and will enable EKF to meet the increasing demands of its growing customer base. And recently on X (Twitter) - EKF develops high-quality diagnostic enzymes, proteins, reagents, and other bio-materials for diverse health and industrial life sciences applications, supporting clinicians and scientists in their work. EKF current website description - To perhaps further demonstrate the significant gap in the market that EKF is looking to exploit, and just to add peptides (proteins) into the vocabulary, the following recent request caught my attention- Peptide production via a fermentation platform We are seeking to produce peptides through fermentation. The ideal partner would be able to provide the expertise, technology, and support for a more complete solution. However, we are eager to collaborate with experts in this space focused on each step of the process. These include the use of a host organism (preferably yeast) to produce peptides, scalable fermentation technology, downstream processing like the purification of the peptides, and technical support to integrate the platform into the production facilities. Full details and interactions etc - Halo is an AI-powered partnering platform for R&D teams. Fill in blind spots. Expand your networks. Bring innovations to market faster. |
Posted at 01/5/2024 13:29 by wan Staying with testing for Diabetic ketoacidosis (DKA) via BHB (EKF Diagnostics) and GLP-1 agonists (multiple Global Pharmaceutical Co's prescription weight loss medicines).Most of EKF's BHB sales are from the US, where testing for ketoacidosis is relatively routine, and where there is also a very high level of prescription and usage of GLP-1 agonists and SGLT2 inhibitors. It has been reported that glucagon-like peptide 1(GLP1) receptor agonists may predispose patients to DKA, and it has also been reported that sodium-glucose co-transporter 2 (SGLT2) inhibitors also raise the risk in patients with type 2 diabetes regardless of the duration of exposure. In the UK NICE state the following: Contraindications and cautions Do not prescribe a GLP-1 receptor agonist to people with: Ketoacidosis. So one assumes that testing for ketoacidosis could be required in the UK? I also noticed the following recently: > Prior to any prescription – record baseline HBA1c and weight (NB: EKF also manufacture desktop point-of-care analyzers for HbA1c, suitable for doctors surgeries/pharmacy/ hospitals etc). > Do not prescribe a GLP-1 receptor agonist to people with • Ketoacidosis. > Diabetic ketoacidosis has been reported in patients with type 2 diabetes on a combination of a GLP-1 receptor agonist and insulin who had doses of concomitant insulin rapidly reduced or discontinued. [...] And the following recently in Europe regarding 'non-diabetic' patients: ABSTRACT Background: Tirzepatide is a novel glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor agonist. It was recently approved for diabetes control and weight reduction in non-diabetic patients. Case description: We report the first case of ketoacidosis after the use of tirzepatide in an obese non-diabetic patient, secondary to the possibility of starvation ketoacidosis and insulin resistance. Conclusion: The dual-acting GLP-1 and GIP receptor agonists, tirzepatide, can induce ketoacidosis in obese non-diabetic patients. Received: 06/02/2024 Accepted: 19/02/2024 Published: 11/03/2024 TIRZEPATIDE-INDUCED KETOACIDOSIS IN NON-DIABETIC PATIENTS : Iqbal PMR, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. EJCRIM 2024;11:doi:10.12890 Consequently, testing for ketoacidosis could be on a very steep growth trajectory, and not just in the US. To quote a phrase from the film Jaws; you are going to need a bigger vessel(fermentation vessel)! But of course EKF already have a much larger vessel, a 14,500 liter stainless steel fermenter (previously their largest fermenter was 1,600 liter). Furthermore, EKF has reported that their new fermentation facility is capable of producing 12 months’ inventory from just one 3,000L fermentation run (from one of the smaller vessels), which is a scale EKF has never been able to achieve historically, thereby enabling margin improvement and opening capacity for new customers, and potential to address larger market opportunities. |
Posted at 28/4/2024 10:31 by wan Readers will already be aware of the very positive effects from EKF's new fermentation facility being able to produce 12 months’ inventory from just one 3,000L fermentation run, which is a scale EKF has never been able to achieve historically, thereby enabling margin improvement and opening capacity for new customers.Staying with increased capacity and the production of BHB: EKF's Thermo Fisher White Label contract for β-HB LiquiColor(produced by EKF) appears to be fully live with multiple Fisherbrand BHB products priced and available (EKF did state that "conversion of Thermo Fisher white label will be a focus in the US"). And I also note that a competitor BHB product, not manufactured in the US (manufacturer ultimately owned by a Chinese company), has a "discontinued by the supplier" note (which is quite interesting in itself) and a redirection to the Fisherbrand™ Beta-hydroxybutyrate (BHB) Liquicolor™ product. Apart from being very beneficial to both Thermo and EKF, this also fits well with supply chain resilience/made in the USA measures referred to in post 14 - That US buyers should reduce their dependency on medical products sourced from China(and other countries of concern) and seek alternatives, ideally manufactured in the US in order to improve supply chain security and resilience. Many companies are therefore taking a closer look at their supply chains. |
Posted at 23/3/2024 09:07 by wan EKF is a global diagnostics and biotechnology company manufacturing and delivering diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.After rationalisations and investments made over the last two years resulting in a simplified structure of two divisions, Point-of-Care and Life Sciences, EKF is now well placed to deliver sustainable growth and improved returns. In a buy recommended brokers note, Panmure Gordon said: “EKF looks circa 30% undervalued on the basis of the point of care division alone, encouraging progress with customers in the new fermentation facility offers the potential for further upside. Emerging from its transitional period EKF is well positioned for a return to more consistent performance and a strengthening cash position.” Singer Capital Markets broker note: EKF’s FY23 results are in line / slightly ahead of expectations. Growth drivers remain intact in both Point-of-Care and Life Sciences and, with a greater focus on core products, margins should continue to improve from here. This is key to supporting a re-rating and we see considerable value at current levels. With profit forecasts unchanged, we roll forwards our valuation to FY24 and increase our TP to 36p, reiterating our Buy recommendation. (full note available via Research Tree - It's perhaps somewhat underappreciated that EKF has a well-established and comprehensive base of installed Point-of-Care diagnostic users supported by high-quality global distribution channels. In 2023, EKF sold over 12,000 Point-of-Care analysers, resulting in the sale and manufacture of over 95 million individual test consumables. The installed base of diagnostic instruments is currently delivering guaranteed recurring revenues of £35-40m, and is set for further growth in 2024 and beyond (cue Panmure Gordon's point-of-care comment above). In Life Sciences, EKF has invested in a new facility with a full range of fermenters of different capacity, including increased downstream processing, offering contract fermentation services for clinically important enzymes and proteins. EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine. Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. Customer onboarding has commenced with several fermentation runs completed that will generate revenue in 2024 and will lead to further growth in 2024 as the new customers scale up. With a full range of fermenters of different capacity now online, EKF will look to scale up output throughout 2024 and to add additional customers throughout the current year. EKF are also in active discussions with new fermentation customers for development and scale-up opportunities to come on-line late 2024 and through to 2025. EKF's Outlook Statement: • Investment in our focused core products within Hematology, Diabetes and β-HB will drive further, sustainable growth • Strengthening relationships with key global partners and distribution channels to increase our existing market share in identified core product ranges • 2024 will see the completion of the rationalisation process, resulting in a streamlined core business portfolio, and expansion of fermentation offering • EKF is well placed to deliver growth and improved returns from the investments made over the last two years Presentation - Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
Posted at 01/7/2022 14:23 by wan 'On plan' news -Industry News: EKF to highlight specific glycemic control marker at AACC 2022 EKF Diagnostics exhibiting range of tests and analyzers on Booth #3637 30 Jun 2022 EKF Diagnostics, a global in vitro diagnostics company, will be at the 2022 AACC Clinical Lab Expo, Chicago IL, July 26-28, exhibiting its range of laboratory and point-of-care diagnostics products on Booth #3637. This includes the FDA cleared Lucica® Glycated Albumin-L test kit, manufactured by Asahi Kasei Pharma Corporation and sold exclusively in the U.S. by EKF. A specific, quantitative test for glycated albumin, it is one of the most widely published methods worldwide used for the intermediate term monitoring of glycemic control in diabetes patients. Lucica® Glycated Albumin-L is an enzymatic methodology for use on compatible clinical chemistry analyzers with open channel capability, making it accurate and cost-effective to perform. It determines both glycated albumin and total albumin in separate reactions and the results are expressed as a ratio (%), minimizing differences in albumin concentrations between patients. Lucica® is also standardized to an established reference material. “The Lucica® Glycated Albumin-L is sold exclusively by EKF Diagnostics in the U.S. and complements our existing diabetes product range, offering its own utility as a specific, intermediate glycemic control marker,” said Shane O’Neill, Global Director of Scientific Affairs, EKF Diagnostics. Alongside its range of clinical chemistry tests and diagnostics analyzers, also available to view on EKF’s Booth at AACC will be its newly launched EKF Link digital connectivity solution. The downloadable software package offers secure management of point-of-care (POC) analyzers and associated data on one centralized platform. This delivers essential digital connectivity with traceability that is increasingly required for safe, secure, and effective POC testing using analyzers in many differing locations. EKF Link middleware is an open and flexible solution which can be interfaced to all vendors’ POC analyzers, including EKF’s own portfolio, to enable real-time remote management of data, including patient test results, QC results, operator management, and analyzer configuration. The user-friendly software allows POC analyzers to connect to a hospital or laboratory’s IT system, enabling data transfer from the remote analyzers for subsequent processing. This provides hospitals, laboratories, and clinicians with the functionality to manage and evaluate their patient and operator data easily and securely. EKF’s portfolio of POC diagnostic devices includes Hemo Control and DiaSpect Tm hemoglobin analyzer ranges, as well as Quo-Lab and Quo-Test HbA1c analyzers. All of these can now be digitally connected from anywhere and securely accessed remotely at any time using EKF Link, thereby enhancing their capabilities. Recall from the EKF Link RNS - The development and launch of EKF Link has been driven by customer demand and designed in partnership with hospital POC managers to ensure the software meets their specific needs. EKF Link provides the Company with improved competitive positioning for future POC contract tenders and new accounts, and increases the attractiveness of the EKF product portfolio to existing customers against currently available technologies. Mike Salter, CEO, of EKF Diagnostics said: "As part of our strategy to enhance our POC analyser portfolio and technology offering, we are pleased to announce that we have successfully launched EKF Link enabling practitioners to analyse their patients' results remotely, easily and securely. EKF Link provides our POC diagnostic devices with a connectivity advantage which positions us well for tenders and new accounts. This is particularly true in Europe and North America, where a connectivity solution is commonly a part of the specification. EKF Link has the added benefit that it can be installed wherever it is needed, on a PC or a central server, allowing hospitals and laboratories, technicians and clinicians to access results from various settings, reducing workload whilst increasing the security of handling patient data. "This new product launch shows our responsiveness to our customer base and increasing demand for data management capabilities. It extends the utility of our installed instrument base and provides EKF with a key advantage for further new business opportunities." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
